Pembrolizumab Plus Axitinib and the Future of Further-line mRCC Treatments

Updated analysis of KEYNOTE-426: pembro plus axitinib vs sunitinib in mRCCПодробнее

Dr. Rini on Managing the Toxicity of Pembrolizumab Plus Axitinib in mRCCПодробнее

KEYNOTE-426 - Pembrolizumab plus axitinib versus sunitinib for mRCCПодробнее

Dr. Powles on FDA Approval of Pembrolizumab Plus Axitinib in Advanced RCCПодробнее

Latest developments in the treatment of mRCCПодробнее

KEYNOTE-426 rationale and results: pembro plus axitinib vs. sunitinib in mRCCПодробнее

Dr. Rini Discusses Pembrolizumab Plus Axitinib in mRCCПодробнее

Pembrolizumab Plus Axitinib in the Second-line and Beyond for mRCCПодробнее

Longer Term Outcomes With Pembrolizumab Plus Axitinib for Advanced RCCПодробнее

Dr. Cost on Pembrolizumab Plus Axitinib in Patients With RCCПодробнее

Extended Follow-Up From a Trial of Pembrolizumab Plus Axitinib for Advanced Renal Cell CarcinomaПодробнее

Special series on RCC: First-line treatment strategies for mRCC with Dr. Mari and Dr. MarandinoПодробнее

Dr. Choueiri on Avelumab Plus Axitinib in mRCCПодробнее

Dr. Vaishampayan on Axitinib Plus Pembrolizumab in Advanced RCCПодробнее

Special series on RCC: Beyond first-line treatment strategies for mRCC with Dr. Mari and Dr. Cicc...Подробнее

Axitinib plus pembrolizumab in advanced RCCПодробнее

Real-world treatment outcomes of 1L axitinib + pembrolizumab in patients with advanced RCC in the USПодробнее

Key Data From ASCO GU 2019 on mRCC: Pembrolizumab and Axitinib as First-Line TherapyПодробнее

KEYNOTE-426 studyПодробнее